Study identification

PURI

https://redirect.ema.europa.eu/resource/47538

EU PAS number

EUPAS47537

Study ID

47538

Official title and acronym

Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era (ILD vMDT)

DARWIN EU® study

No

Study countries

Argentina
Australia
Austria
Belgium
Brazil
Canada
Chile
Croatia
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
India
Indonesia
Ireland
Italy
Japan
Luxembourg
Malaysia
Mexico
New Zealand
Norway
Peru
Poland
Portugal
Romania
Singapore
South Africa
Spain
Sweden
Switzerland
Türkiye
United Kingdom
United Kingdom (Northern Ireland)
United States

Study description

This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis. An on-line survey will be sent via email to dedicated and non-dedicated ILD centres and countries within both mature and expanding economies (featuring a wide range of health systems and health infrastructures) across key global regions. The study will take an inclusive approach, welcoming responses from all countries and participants involved in the diagnosis of ILD.

Study status

Finalised
Research institutions and networks

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Lough Graham

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim
Study protocol
Initial protocol

REG ILD eMDT protocol REG-RES2021 v1

English (2.06 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable